1 / 34

Tay-Sachs Disease: Pipeline Intelligence, 2019

CmaxInsightu2019s, u201cTay-Sachs Disease: Pipeline Intelligence, 2019u201d, report provides comprehensive insights about pipeline drugs across this Indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Tay-Sachs Disease.<br>Highlights and Scope of the Report<br>uf0b7 Establish a comprehensive understanding of key competitor information, analysis, and insights to improve R&D strategies<br>uf0b7 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage<br>uf0b7 Discover in-licensing and out-licensing strategies by identifying potential partners with progressing projects for Tay-Sachs Disease to enhance and expand business potential and scope<br>uf0b7 Plan mergers and acquisitions successfully by identifying major players with the most promising pipeline therapeutics in the target demographic<br>uf0b7 Our extensive in-depth analysis on therapy portfolio support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the dormant or discontinued drugs<br>uf0b7 Develop strategic initiatives by understanding the focus areas of leading companies<br>uf0b7 Assess challenges and opportunities that influence Tay-Sachs Disease R&D

cmaxinsight
Download Presentation

Tay-Sachs Disease: Pipeline Intelligence, 2019

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tay-Sachs Disease: Pipeline Intelligence, 2019

  2. Tay-Sachs Disease: Pipeline Intelligence, 2019 Introduction CmaxInsight’s, “Tay-Sachs Disease: Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this Indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Tay-Sachs Disease. Highlights and Scope of the Report Establish a comprehensive understanding of key competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Discover in-licensing and out-licensing strategies by identifying potential partners with progressing projects for Tay-Sachs Disease to enhance and expand business potential and scope Plan mergers and acquisitions successfully by identifying major players with the most promising pipeline therapeutics in the target demographic Our extensive in-depth analysis on therapy portfolio support the client in decision- making process regarding their therapeutic portfolio by identifying the reason behind the dormant or discontinued drugs Develop strategic initiatives by understanding the focus areas of leading companies Assess challenges and opportunities that influence Tay-Sachs Disease R&D Secondary resources such as Company Websites, Annual Reports, Financial Reports, Analyst Reports, Investor Presentations, Press Releases, web-casts Industry Trade Journals, Pubmed, NCBI, Oxford and other literature and in-house analysis by CmaxInsight’s team of industry experts are referred for preparing the report. Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated mechanism of action. 2 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  3. Tay-Sachs Disease: Pipeline Intelligence, 2019 Insights Pipeline Drugs Therapeutic Assessment Disease Overview Insights Leading Company Analysis Clinical Trial Landscape Mergers, Acquisitions & Collaboration Deals 3 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  4. Tay-Sachs Disease: Pipeline Intelligence, 2019 Executive Summary Snapshot Tay-Sachs Disease Snapshot Pipeline at a Glance Phase I Phase III Phase II Pre-Clinical & Discovery Leading Companies & their Most Prominent Targets •Target •Target Company 1 Company 2 Company 3 Company 4 •Target •Target Market Drivers Market Barriers 4 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  5. Tay-Sachs Disease: Pipeline Intelligence, 2019 Table of Contents Introduction ..................................................................................................................... 1 Insights ............................................................................................................................ 3 Executive Summary Snapshot ........................................................................................... 4 Disease Overview ............................................................................................................. 8 Causes .................................................................................................................................... 8 Symptoms .............................................................................................................................. 8 Pathophysiology ..................................................................................................................... 8 Diagnosis ................................................................................................................................ 8 Treatment .............................................................................................................................. 8 Epidemiology.......................................................................................................................... 8 FSHD Research and Development ..................................................................................... 8 Competitive Landscape ..................................................................................................... 9 Comparative Analysis ............................................................................................................. 9 Pipeline Therapeutics ...................................................................................................... 10 Mid Stage Products (Phase II) .......................................................................................... 11 Comparative Analysis ........................................................................................................... 11 IB1001: IntraBio .............................................................................................................. 12 Product Description ............................................................................................................. 12 Product Profile ..................................................................................................................... 12 Research and Development ................................................................................................. 13 Clinical Trial Landscape ........................................................................................................ 13 Product Development Activities .......................................................................................... 13 Key Development Milestone ............................................................................................... 13 Early Stage Products (Phase I) .......................................................................................... 14 Comparative Analysis ........................................................................................................... 14 AXO-AAV-GM2: Axovant ................................................................................................. 15 Product Description ............................................................................................................. 15 Product Profile ..................................................................................................................... 15 Research and Development ................................................................................................. 16 Clinical Trial Landscape ........................................................................................................ 16 Product Development Activities .......................................................................................... 16 Key Development Milestone ............................................................................................... 16 Pre-clinical and Discovery Products .................................................................................. 17 Comparative Analysis ........................................................................................................... 17 Drug for the treatment of Tay–Sachs disease: Recursion Pharmaceuticals ........................ 18 Product Description ............................................................................................................. 18 Product Profile ..................................................................................................................... 18 Research and Development ................................................................................................. 19 Product Development Activities .......................................................................................... 19 5 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  6. Tay-Sachs Disease: Pipeline Intelligence, 2019 Key Development Milestone ............................................................................................... 19 Featured Clinical Evidence for Tay-Sachs Disease ............................................................. 20 Universities working on Tay-Sachs Disease ...................................................................... 21 Patient Support and Advocacy Resources ........................................................................ 22 Therapeutic Assessment .................................................................................................. 23 Assessment by Route of Administration.............................................................................. 23 Assessment by Stage and Route of Administration ............................................................. 24 Assessment by Molecule Type ............................................................................................. 25 Assessment by Stage and Molecule Type ............................................................................ 26 Assessment by Target .......................................................................................................... 27 Assessment by Stage and Target ......................................................................................... 28 Dormant and Discontinued Products ............................................................................... 29 Comparative Analysis ........................................................................................................... 29 Drug name: Company name ............................................................................................ 30 Product Description ............................................................................................................. 30 Research and Development ................................................................................................. 30 Product Development Activities .......................................................................................... 30 Reason for Dormancy / Discontinuation ............................................................................. 30 Leading Companies Analysis ............................................................................................ 31 Company: Company Description ......................................................................................... 31 Company, Total Revenue ..................................................................................................... 32 Revenue by Business Segments ........................................................................................... 32 Geography-Wise Revenue ................................................................................................... 33 Price ................................................................................................................................ 34 About CmaxInsight .......................................................................................................... 34 Contact Us ....................................................................................................................... 34 Disclaimer ....................................................................................................................... 34 6 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  7. Tay-Sachs Disease: Pipeline Intelligence, 2019 List of Tables Table 1: Total Products for Tay-Sachs Disease .......................................................................... 9 Table 3: Mid Stage Products (Phase II) .................................................................................... 11 Table 3: Early Stage Products (Phase I) .................................................................................... 14 Table 4: Pre-clinical and Discovery Stage Products ................................................................. 17 Table 5: List of featured Clinical Evidence for Tay-Sachs Disease ........................................... 20 Table 6: List of Universities working on Tay-Sachs Disease ..................................................... 21 Table 7: List of Patient Support and Advocacy Resources ....................................................... 22 Table 8: Assessment by Route of Administration .................................................................... 23 Table 9: Assessment by Stage and Route of Administration ................................................... 24 Table 10: Assessment by Molecule Type ................................................................................. 25 Table 11: Assessment by Stage and Molecule Type ................................................................ 26 Table 12: Assessment by Target .............................................................................................. 27 Table 13: Assessment by Stage and Target ............................................................................. 28 Table 14: Dormant Products .................................................................................................... 29 Table 15: Discontinued Products ............................................................................................. 29 Table 16: Company Profile, 2018 ............................................................................................. 31 List of Figures Figure 1: Number of Products under Development for Tay-Sachs Disease .............................. 9 Figure 3: Mid Stage Products (Phase II) ................................................................................... 11 Figure 3: Early Stage Products (Phase I) .................................................................................. 14 Figure 4: Assessment by Route of Administration .................................................................. 23 Figure 5: Assessment by Stage and Route of Administration .................................................. 24 Figure 6: Assessment by Molecule Type .................................................................................. 25 Figure 7: Assessment by Stage and Molecule Type ................................................................. 26 Figure 8: Assessment by Target ............................................................................................... 27 Figure 9: Assessment by Stage and Target .............................................................................. 28 Figure 10: Dormant and Discontinued Products ..................................................................... 29 Figure 11: Company, Total Revenue ........................................................................................ 32 Figure 12: Company, Revenue by Business Segments............................................................. 32 Figure 13: Company, Geography-Wise Revenue ..................................................................... 33 7 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  8. Tay-Sachs Disease: Pipeline Intelligence, 2019 Disease Overview Tay-Sachs disease is a rare, neurodegenerative disorder in which deficiency of an enzyme (hexosaminidase A) results in excessive accumulation of certain fats (lipids) known as gangliosides in the brain and nerve cells. This abnormal accumulation of gangliosides leads to progressive dysfunction of the central nervous system. This disorder is categorized as a lysosomal storage disease. Causes Symptoms Pathophysiology Diagnosis Treatment Unmet Needs Epidemiology FSHD Research and Development 8 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  9. Tay-Sachs Disease: Pipeline Intelligence, 2019 Competitive Landscape Comparative Analysis Figure 1: Number of Products under Development for Tay-Sachs Disease 10 9 Filed Number of Products 8 Phase III Phase II 6 5 Phase I Pre-Clinical 4 3 3 Discovery 2 2 2 Dormant 2 1 Discontinued 0 Stage of Development Source: CmaxInsight Table 1: Total Products for Tay-Sachs Disease Stage of Development Filed Phase III Phase II Phase I Pre-Clinical Discovery Dormant Discontinued Number of Products Source: CmaxInsight 9 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  10. Tay-Sachs Disease: Pipeline Intelligence, 2019 Pipeline Therapeutics 1 Avadel Pharmaceuticals 1 Arena Pharmaceuticals 1 Filed Balance Therapeutics 1 Phase III Evotec AG Phase II 1 GlaxoSmithKline Phase I 1 Heptares Therapeutics Pre-clinical 1 2 1 Jazz Pharmaceuticals Discovery 1 1 Johnson & Johnson Dormant 1 NLS Pharma Discontinued Company Name 1 Ono Pharmaceutical 1 OptiNose 1 Pfizer 1 Reset Therapeutics 1 Roche 1 Sanofi 1 Seelos Therapeutics 1 Suven Life Sciences 1 Taisho Pharmaceutical 1 Takeda 1 Theranexus 0 1 2 3 4 5 Number of Products 10 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  11. Tay-Sachs Disease: Pipeline Intelligence, 2019 Mid Stage Products (Phase II) Comparative Analysis Figure 2: Mid Stage Products (Phase II) 10 Total Active Products 9 8 Number of Products 6 Phase I Products 2 4 2 0 Stage of Development Source: CmaxInsight Table 2:Mid Stage Products (Phase II) Drug name Company Phase MoA RoA Molecule type Source: CmaxInsight 11 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  12. Tay-Sachs Disease: Pipeline Intelligence, 2019 IB1001: IntraBio Product Description Product Description Drug Name Generic Name Alias Name Chemical Name Chemical Formula Molecular Weight CAS Registration No. Source: CmaxInsight Product Profile Product Profile Drug Name Company Product Type Therapy Area Indications Highest Stage of Development Designation Route of Administration Formulation Target Mechanism of Action Technology Molecule Type Drug Origin Source: CmaxInsight 12 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  13. Tay-Sachs Disease: Pipeline Intelligence, 2019 Research and Development Clinical Studies Clinical Trials Description Intervention (Sponsor) NCT No. Start date 1 ⁰ Phase Status Indication Completion Source: CmaxInsight Clinical Trial Landscape Trial name (Status: )Study Design & Details Phase Sponsor Population Prior Rx Study Drug/Regimen Comparator/Regimen Endpoints: Start date 1⁰ Completion Trial ID Study Design Location Source: CmaxInsight Product Development Activities Product Deals, 2018 Licensed From Licensing Type Collaboration Partner Institutional Partner Source: CmaxInsight Designation Deals Patent Technology Funding & financing Key Development Milestone Xxxxxxx 13 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  14. Tay-Sachs Disease: Pipeline Intelligence, 2019 Early Stage Products (Phase I) Comparative Analysis Figure 3: Early Stage Products (Phase I) 10 Total Active Products 9 8 Number of Products 6 Phase I Products 2 4 2 0 Stage of Development Source: CmaxInsight Table 3:Early Stage Products (Phase I) Drug name Company Phase MoA RoA Molecule type Source: CmaxInsight 14 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  15. Tay-Sachs Disease: Pipeline Intelligence, 2019 AXO-AAV-GM2: Axovant Product Description Product Description Drug Name Generic Name Alias Name Chemical Name Chemical Formula Molecular Weight CAS Registration No. Source: CmaxInsight Product Profile Product Profile Drug Name Company Product Type Therapy Area Indications Highest Stage of Development Designation Route of Administration Formulation Target Mechanism of Action Technology Molecule Type Drug Origin Source: CmaxInsight 15 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  16. Tay-Sachs Disease: Pipeline Intelligence, 2019 Research and Development Clinical Studies Clinical Trials Description Intervention (Sponsor) NCT No. Start date 1 ⁰ Phase Status Indication Completion Source: CmaxInsight Clinical Trial Landscape Trial name (Status: )Study Design & Details Phase Sponsor Population Prior Rx Study Drug/Regimen Comparator/Regimen Endpoints: Start date 1⁰ Completion Trial ID Study Design Location Source: CmaxInsight Product Development Activities Product Deals, 2018 Licensed From Licensing Type Collaboration Partner Institutional Partner Source: CmaxInsight Designation Deals Patent Technology Funding & financing Key Development Milestone Xxxx 16 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  17. Tay-Sachs Disease: Pipeline Intelligence, 2019 Pre-clinical and Discovery Products Comparative Analysis Figure 6: Pre-clinical and Discovery Stage Products Total Active Products 9 10 8 Number of Products 6 Pre-Clinical Products 2 4 Discovery Products 2 2 0 Stage of Development Source: CmaxInsight Table 4:Pre-clinical and Discovery Stage Products Drug name Company Phase MoA RoA Molecule type Source: CmaxInsight 17 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  18. Tay-Sachs Disease: Pipeline Intelligence, 2019 Drug for the treatment of Tay–Sachs disease: Recursion Pharmaceuticals Product Description Product Description Drug Name Generic Name Alias Name Chemical Name Chemical Formula Molecular Weight CAS Registration No. Source: CmaxInsight Product Profile Product Profile Drug Name Company Product Type Therapy Area Indications Highest Stage of Development Designation Route of Administration Formulation Target Mechanism of Action Technology Molecule Type Drug Origin Source: CmaxInsight 18 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  19. Tay-Sachs Disease: Pipeline Intelligence, 2019 Research and Development Pre-clinical Studies XXXXXXX Product Development Activities Product Deals, 2018 Licensed From Licensing Type Collaboration Partner Institutional Partner Source: CmaxInsight Designation Deals Patent Technology Funding & financing Key Development Milestone XXXXXX 19 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  20. Tay-Sachs Disease: Pipeline Intelligence, 2019 Featured Clinical Evidence for Tay-Sachs Disease Product-related evidence Pipeline candidates Non-product related Evidence Table 5: List of featured Clinical Evidence for Tay-Sachs Disease Drug name / Issue Source: CmaxInsight Source: CmaxInsight Title Journal Date Note: This section provides Tay-Sachs Disease-Feature Clinical Evidence for last 5 years Inclusion Criteria Rules • • • • • • • • • • Anything about pipeline drugs Pre-clinical studies of products Real-life experience with marketed therapies Biomarkers Risk factors Patient segmentation Disease progression Diagnosis Treatment Pathogenesis 20 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  21. Tay-Sachs Disease: Pipeline Intelligence, 2019 Universities working on Tay-Sachs Disease Table 6: List of Universities working on Tay-Sachs Disease Drug name / Issue Source: CmaxInsight Research Focus & News Source 21 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  22. Tay-Sachs Disease: Pipeline Intelligence, 2019 Patient Support and Advocacy Resources Table 7: List of Patient Support and Advocacy Resources Association Name Source: CmaxInsight Research Focus & news Country Source 22 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  23. Tay-Sachs Disease: Pipeline Intelligence, 2019 Therapeutic Assessment Assessment by Route of Administration Figure 4:Assessment by Route of Administration 2 1 Oral Intravenous 1 Intranasal Unspecified 12 Source: CmaxInsight Table 8: Assessment by Route of Administration Route of Administration Oral Intravenous Intranasal Unspecified Number of Products 23 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  24. Tay-Sachs Disease: Pipeline Intelligence, 2019 Assessment by Stage and Route of Administration Figure 5:Assessment by Stage and Route of Administration 1 1 Discovery 1 1 1 Pre-clinical Oral 2 1 Phase I Intravenous 3 Phase II Intranasal 4 Unspecified Phase III 1 Filed 0 1 2 3 4 5 No. of Products Source: CmaxInsight Table 9: Assessment by Stage and Route of Administration Route of Administration Stage of Development Filed Phase III Phase II Phase I Pre-clinical Discovery Phase I Pre-clinical Pre- clinical Discovery Number of Products Oral Intravenous Intranasal Unspecified Source: CmaxInsight 24 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  25. Tay-Sachs Disease: Pipeline Intelligence, 2019 Assessment by Molecule Type Figure 6:Assessment by Molecule Type 1 Small Molecule 3 Biologics 2 Peptide Unspecified 2 Source: CmaxInsight Table 10: Assessment by Molecule Type Molecule Type Small Molecule Biologic Peptide Unspecified Number of Products Source: CmaxInsight 25 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  26. Tay-Sachs Disease: Pipeline Intelligence, 2019 Assessment by Stage and Molecule Type Figure 7:Assessment by Stage and Molecule Type 1 1 Discovery 1 1 1 Pre-clinical Small Molecule 2 1 Phase I Biologic 3 Phase II Peptide 4 Unspecified Phase III 1 Filed 0 1 2 3 4 5 No. of Products Source: CmaxInsight Table 11: Assessment by Stage and Molecule Type Molecule Type Stage of Development Filed Phase III Phase II Phase I Pre-clinical Discovery Phase I Pre-clinical Pre- clinical Discovery Number of Products Small Molecule Biologic Peptide Unspecified Source: CmaxInsight 26 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  27. Tay-Sachs Disease: Pipeline Intelligence, 2019 Assessment by Target Figure 8:Assessment by Target 1 Target 1 3 Target 2 2 Target 3 Target 4 2 Source: CmaxInsight Table 12: Assessment by Target Target Target 1 Target2 Target 3 Target 4 Number of Products Source: CmaxInsight 27 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  28. Tay-Sachs Disease: Pipeline Intelligence, 2019 Assessment by Stage and Target Figure 9:Assessment by Stage and Target 1 1 Discovery 1 1 1 Pre-clinical Target 1 2 1 Phase I Target 2 3 Phase II Target 3 4 Target 4 Phase III 1 Filed 0 1 2 3 4 5 No. of Products Source: CmaxInsight Table 13: Assessment by Stage and Target Target Stage of Development Filed Phase III Phase II Phase I Pre-clinical Discovery Phase I Pre-clinical Pre- clinical Discovery Number of Products Target 1 Target2 Target 3 Target 4 28 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  29. Tay-Sachs Disease: Pipeline Intelligence, 2019 Dormant and Discontinued Products Comparative Analysis Figure 10: Dormant and Discontinued Products Total Active Products 9 10 8 Number of Products 6 Dormant Products 2 4 Discontinued Products 2 2 0 Stage of Development Source: CmaxInsight Table 14: Dormant Products Drug Name Company Stage of Dormancy Source: CmaxInsight Table 15: Discontinued Products Drug Name Company Stage of Discontinuation Source: CmaxInsight 29 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  30. Tay-Sachs Disease: Pipeline Intelligence, 2019 Drug name: Company name Product Description Xxxxx Research and Development Clinical Studies Clinical Trials Description Intervention (Company) NCT No. Start date 1 ⁰ Phase Status Indication Completion Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Xxxxx Source: CmaxInsight Product Development Activities Xxxxxxx Reason for Dormancy / Discontinuation Xxxxxxxx 30 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  31. Tay-Sachs Disease: Pipeline Intelligence, 2019 Leading Companies Analysis Company: Company Description XXXX Table 16: Company Profile, 2018 Company Name Entity Industry Headquarter Year Founded Business Segments Net Revenue Net Income Employees CEO Website Source: CmaxInsight 31 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  32. Tay-Sachs Disease: Pipeline Intelligence, 2019 Company, Total Revenue XXXX Figure 11: Company, Total Revenue Total Revenue (2014-2017) 120 25.00% 100 20.00% Revenue In USD Million 80 15.00% 60 10.00% 40 5.00% 20 0 0.00% 2014 2015 2016 2017 Total Revenue AGR % Source: CmaxInsight Revenue by Business Segments XXXX Figure 12: Company, Revenue by Business Segments REVENUE BY BUSINESS SEGMENT (2018) Other Japan Oceania Middle East Southeast Asia North America Source: CmaxInsight 32 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  33. Tay-Sachs Disease: Pipeline Intelligence, 2019 Geography-Wise Revenue XXXX Figure 13: Company, Geography-Wise Revenue REGION WISE REVENUE (2018) Other Japan Oceania Middle East Southeast Asia North America Source: CmaxInsight 33 ©CmaxInsight|This report is a licensed product and is not to be photocopied

  34. Tay-Sachs Disease: Pipeline Intelligence, 2019 Price Report Name Single User License USD 800 Corporate License USD 2000 Tay-Sachs Disease: Pipeline Intelligence- 2019 About CmaxInsight CmaxInsight is a global market research and consulting firm that specialized in providing high- value customized business research, intelligence reports, and databases across pharmaceutical, life science, and healthcare domain. Our aim is to maximize insight with intelligence which assists the clients in decision making and to address new challenges in a fast-paced healthcare environment. We empower healthcare organization at every stage to make the process rapid, better and accurate. We help our clients in bridging the gaps in their business through screening, prioritization, in-depth commercial assessment, independent evaluation of opportunities which facilitating decision-making; identify potential market opportunities, competitor assessments, and business environment assessment. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavour the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients. Contact Us If you have any queries about this report or would like further information, please contact us at the below given email address. Email: sales@cmaxinsight.com Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, CmaxInsight. 34 ©CmaxInsight|This report is a licensed product and is not to be photocopied

More Related